ORKA (Oruka Therapeutics) General and Admin. Expense : $ Mil (TTM As of Dec. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Oruka Therapeutics General and Admin. Expense?

General and Admin. Expense is the aggregate total of general managing and administering expenses for the company. Oruka Therapeutics's General and Admin. Expense for the six months ended in Dec. 2024 was $0.00 Mil. Oruka Therapeutics does not have enough years/quarters to calculate the General and Admin. Expense for the trailing twelve months (TTM) ended in Dec. 2024.

Oruka Therapeutics General and Admin. Expense Historical Data

The historical data trend for Oruka Therapeutics's General and Admin. Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oruka Therapeutics General and Admin. Expense Chart

Oruka Therapeutics Annual Data

Trend

Dec24

General and Admin. Expense

Oruka Therapeutics Semi-Annual Data
	Dec24
General and Admin. Expense	-

Oruka Therapeutics General and Admin. Expense Calculation

General and Admin. Expense is the aggregate total of general managing and administering expenses for the company.

Oruka Therapeutics General and Admin. Expense Related Terms

Thank you for viewing the detailed overview of Oruka Therapeutics's General and Admin. Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

Oruka Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oruka Therapeutics Inc (NAS:ORKA) » Definitions » General and Admin. Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

855 Oak Grove Avenue, Suite 100, Menlo Park, CA, USA, 94025

Website

https://www.orukatx.com

Oruka Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its lead program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. The company's co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, psoriatic arthritis (PsA), and other conditions. These programs each bind their respective targets at high affinity and incorporate half-life extension technology to increase exposure and decreasing dosing frequency.